1.
Systemic Mesenchymal Stem Cell Treatment Mitigates Structural and Functional Retinal Ganglion Cell Degeneration in a Mouse Model of Multiple Sclerosis.
Gramlich Oliver W, Brown Alexander J, Godwin Cheyanne R, Chimenti Michael S, Boland Lauren K, Ankrum James A et al.
Transl Vis Sci TechnolJul 202021 citationsBasic Science
Systemic mesenchymal stem cells mitigated RGC damage and improved visual function in MS mice, potentially via cholesterol and HIF-1 pathways, offering new therapeutic targets for MS-related vision loss.